nach oben

Erschienen in:

12.04.2019 | leitlinien für die praxis

Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung (Update 2019)

verfasst von: Stephan Radda, Matthias Bolz, Stefan Egger, Vanessa Gasser-Steiner, Martina Kralinger, Stefan Mennel, Christoph Scholda, Ulrike Stolba, Andreas Wedrich, die Netzhautkommission der Österreichischen Ophthalmologischen Gesellschaft

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Diabetes mellitus kann diabetische Retinopathie, diabetisches Makulaödem, Optikusneuropathie, Katarakt, Sekundärglaukom und Fehlfunktionen der äußeren Augenmuskeln verursachen. Die Inzidenz dieser Spätschäden korreliert mit der Dauer des Diabetes und mit dem Grad der metabolischen Kontrolle. Die Empfehlungen der Österreichischen Diabetes Gesellschaft für Diagnose, Therapie und Nachkontrolle werden übersichtsweise und bezogen auf die jeweiligen Stadien der diabetischen Augenerkrankung präsentiert.

Vorheriger Artikel Diabetische Nierenerkrankung (Update 2019)

Nächster Artikel Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2019)

Khadem J, Buzney S, Alich K. Practice patterns in diabetic retinopathy: part 1: analysis of retinopathy follow-up. Arch Ophthalmol. 1999;117(6):815–20.PubMedCrossRef

McCarty C, Taylor K, McKay R, et al. Diabetic retinopathy: effects of national guidelines on the referral, examination and treatment practices of ophthalmologists and optometrists. Clin Exp Ophthalmol. 2001;29(2):52–8.PubMedCrossRef

Wilkinson C, Ferris F, Klein R, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–82.PubMedCrossRef

Hazin R, Colyer M, Lum F, et al. Revisiting diabetes 2000: challenges in establishing nationwide diabetic retinopathy prevention programs. Am J Ophthalmol. 2011;152(5):723–9.PubMedCrossRef

Hammes H, Lemmen K. Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie. Diabetes Stoffwechs. 2002;11(Suppl 2):15–6.

Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15(12):1875–91.PubMedCrossRef

Zhang L, Krzentowski G, Albert A, et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24(7):1275–9.PubMedCrossRef

Stratton I, Kohner E, Aldington S, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 yrs from diagnosis. Diabetologia. 2001;44(2):156–63.PubMedCrossRef

Murphy RP, Nanda M, Plotnick L, et al. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108(2):215–8.PubMedCrossRef

10.

The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care. 2000;23(8):1084–91.PubMedCentralCrossRef

11.

The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874–86.CrossRef

12.

Orchard T, Forrest K, Kuller L, et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001;24(6):1053–9.PubMedCrossRef

13.

Sen K, Misra A, Kumar A, et al. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56(1):1–11.PubMedCrossRef

14.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.PubMedCentralCrossRef

15.

Nasr C, Hoogwerf B, Faiman C, et al. United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Cleve Clin J Med. 1999;66(4):247–53.PubMedCrossRef

16.

Davis M, Fisher M, Gangnon R, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report number 18. Invest Ophthalmol Vis Sci. 1998;39(2):233–52.PubMed

17.

Kinyoun J, Barton F, Fisher M, et al. Detection of diabetic macular edema. Ophthalmoscopy versus photography—Early Treatment Diabetic Retinopathy Study report number 5. The ETDRS Research Group. Ophthalmology. 1989;96(6):746–50.PubMedCrossRef

18.

Gonzalez Villalpando C, Gonzalez Villalpando ME, Martinez Diaz S, et al. A diabetic retinopathy screening program as a strategy for blindness prevention. Arch Med Res. 1997;28(1):129–35.PubMed

19.

Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116(5):914–20.PubMedCrossRef

20.

Baskin DE. Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol. 2010;21(3):172–7.PubMedCrossRef

21.

Tangelder GJ, Van der Heijde RG, Polak BC, et al. Precision and reliability of retinal thickness measurements in foveal and extrafoveal areas of healthy and diabetic eyes. Invest Ophthalmol Vis Sci. 2008;49(6):2627–34.PubMedCrossRef

22.

Browning DJ, Fraser CM. The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema. Am J Ophthalmol. 2008;145(1):149–54.PubMedCrossRef

23.

Bolz M, Ritter M, Schneider M, et al. A systematic correlation of angiography and high-resolution optical coherence tomography in diabetic macular edema. Ophthalmology. 2009;116(1):66–72.PubMedCrossRef

24.

Early Treatment Diabetic Retinopathy Study Research Group. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Ophthalmology. 1991;98(Suppl 5):834–40.

25.

Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabet Med. 2002;19(4):285–91.PubMedCrossRef

26.

Kuo HK, Hsieh HH, Liu RT. Screening for diabetic retinopathy by one-field, non-mydriatic, 45 degrees digital photography is inadequate. Ophthalmologica. 2005;219(5):292–6.PubMedCrossRef

27.

The Early Treatment Diabetic Retinopathy Study Research Group. Case reports to accompany Early Treatment Diabetic Retinopathy Study reports 3 and 4. Int Ophthalmol Clin. 1987;27(4):273–333.CrossRef

28.

Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;5(1):823–33.

29.

Lindgren G, Lindblom B. Causes of vitreous hemorrhage. Curr Opin Ophthalmol. 1996;7(3):13–9.PubMedCrossRef

30.

Fong D, Ferris F, Davis M, et al. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1999;127(2):137–41.PubMedCrossRef

31.

Antcliff R, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14(4):223–32.PubMedCrossRef

32.

The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287(19):2542–51.CrossRef

33.

Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987;94(7):761–74.CrossRef

34.

Kohner E, Stratton I, Aldington S, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18(3):178–84.PubMedCrossRef

35.

The Diabetes Control and Complications Trial. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 1995;113(1):36–51.CrossRef

36.

Squirrell D, Bhola R, Bush J, et al. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol. 2002;86(5):565–71.PubMedPubMedCentralCrossRef

37.

Flesner P, Sander B, Henning V, et al. Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. Acta Ophthalmol Scand. 2002;80(1):19–24.PubMedCrossRef

38.

Chung J, Kim MY, Kim HS, et al. Effect of cataract surgery on the progression of diabetic retinopathy. J Cataract Refract Surg. 2002;28(4):626–30.PubMedCrossRef

39.

Cunha-Vaz J. Lowering the risk of visual impairment and blindness. Diabet Med. 1998;15(Suppl 4):S47–S50.PubMedCrossRef

40.

41.

Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118(12):e5–e14.PubMedPubMedCentralCrossRef

42.

Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–77.PubMedPubMedCentralCrossRef

43.

Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–51.PubMedCrossRef

44.

Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399–405.PubMedPubMedCentralCrossRef

45.

Elman MJ, Bressler NM, Qin H, et al. Expanded 2‑year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14.PubMedPubMedCentralCrossRef

46.

Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.PubMedCrossRef

47.

Elman MJ, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5‑year randomized trial results. Ophthalmology. 2015;122(2):375–81. https://doi.org/10.1016/j.ophtha.2014.08.047.PubMedCrossRef

48.

Korobelnik JF, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54. https://doi.org/10.1016/j.ophtha.2014.05.006.PubMedCrossRef

49.

The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–203. https://doi.org/10.1056/NEJMoa1414264.PubMedCentralCrossRef

50.

51.

Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–25.PubMedCrossRef

52.

53.

Boyer DS. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–14. https://doi.org/10.1016/j.ophtha.2014.04.024.PubMedCrossRef

54.

Campochiaro PA. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.e2. https://doi.org/10.1016/j.ophtha.2010.12.028.PubMedCrossRef

55.

The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol. 1976;81(4):383–96.CrossRef

56.

The Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study report no. 3. Int Ophthalmol Clin. 1987;27(4):254–64.CrossRef

57.

Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6):1009–27.PubMedCrossRef

58.

Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505–37.PubMedPubMedCentral

59.

Bodanowitz S, Hesse L, Weinand F, et al. Vitrectomy in diabetic patients with a blind fellow eye. Acta Ophthalmol Scand. 1996;74(1):84–8.PubMedCrossRef

60.

Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89(7):567–72.CrossRef

61.

Kohner EM, Barry PJ. Prevention of blindness in diabetic retinopathy. Diabetologia. 1984;26(3):173–9.PubMedCrossRef

62.

Rand LI, Prud’homme GJ, Ederer F, et al. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) report no. 10. Invest Ophthalmol Vis Sci. 1985;26(7):983–91.PubMed

63.

Dogru M, Nakamura M, Inoue M, et al. Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation. Jpn J Ophthalmol. 1999;43(3):217–24.PubMedCrossRef

64.

Stanga PE, Papayannis A, Tsamis E, et al. New findings in diabetic maculopathy and proliferative disease by swept-source optical coherence tomography angiography. Dev Ophthalmol. 2016;56:113–21.PubMedCrossRef

65.

De Barros Garcia J, Isaac DLC, Avila M. Diabetic retinopathy and OCT angiography: clinical findings and future perspectives. Int J Retina Vitreous. 2017;3:14.PubMedPubMedCentralCrossRef

66.

Cao D, Yang D, Huang Z, et al. Optical coherence tomography angiography discerns preclinical diabetic retinopathy in eyes of patients with type 2 diabetes without clinical diabetic retinopathy. Acta Diabetol. 2018;55(5):469–77.PubMedCrossRef

67.

Schreur V, Domanian A, Liefers B, et al. Morphological and topographical appearance of microaneurysms on optical coherence tomography angiography. Br J Ophthalmol. 2018;.

68.

Gross JG, Glassman AR, et al. A novel treatment for proliferative diabetic retinopathy: anti-vascular endothelial growth factor therapy. JAMA Ophthalmol. 2016;134(1):13–4. https://doi.org/10.1001/jamaophthalmol.2015.5079.PubMedCrossRef

Titel: Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung (Update 2019)
verfasst von: Stephan Radda
Matthias Bolz
Stefan Egger
Vanessa Gasser-Steiner
Martina Kralinger
Stefan Mennel
Christoph Scholda
Ulrike Stolba
Andreas Wedrich
die Netzhautkommission der Österreichischen Ophthalmologischen Gesellschaft
Publikationsdatum: 12.04.2019
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe Sonderheft 1/2019
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-019-1445-1

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2019

Diabetische Nierenerkrankung (Update 2019)

Lipide: Diagnostik und Therapie bei Diabetes mellitus (Update 2019)

Individualisierung der antihypertensiven Therapie bei Patienten mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2019)

Positionspapier: Operation und Diabetes mellitus (Update 2019)

Lebensstil: körperliche Aktivität und Training in der Prävention und Therapie des Typ 2 Diabetes mellitus (Update 2019)

Kontinuierliche Glukosemessung (CGM – Continuous Glucose Monitoring) bei Diabetes mellitus (Update 2019)